Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22751123 | 0.89 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL18250321 | 0.85 | NPC1 (0.39) | HSP90AA1ALDH1A1 | |
| SCHEMBL9967701 | 0.83 | ALDH1A1 (0.36) | HSP90AA1HSP90AB1ALDH1A1GAA | |
| SCHEMBL15341602 | 0.82 | KMT2A (0.34) | ALDH1A1GAA | |
| SCHEMBL22843159 | 0.82 | MAPT (0.33) | — | |
| SCHEMBL24666097 | 0.82 | CYP11B1 (0.33) | — | |
| SCHEMBL25619086 | 0.82 | CACNA1G (0.32) | — | |
| SCHEMBL18250286 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL15133211 | 0.79 | MPO (0.37) | ALDH1A1GAA | |
| SCHEMBL15133213 | 0.79 | NR5A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-08-03 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-06-22 | — | — | US | disclosed |
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | VIIV HEALTHCARE COMPANY | 2023-02-09 | — | — | US | disclosed |
| US-20220089598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-03-24 | — | — | US | disclosed |
| WO-2022015975-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-9617310-B2 | Inhibitors of hepatitis C virus | GILEAD SCIENCES, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | HSP90AA1 1058/4885HSP90AB1 729/4885ALDH1A1 776/4885 |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | HSP90AA1 2367/4885HSP90AB1 2140/4885ALDH1A1 164/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | HSP90AA1 2367/4885HSP90AB1 2140/4885ALDH1A1 164/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | HSP90AA1 2367/4885HSP90AB1 2140/4885ALDH1A1 164/4885 |
| US-20110230350-A1 | ARYL-AND HETARYLSULFONAMIDES AS ACTIVE INGREDIENTS AGAINST ABIOTIC PLANT STRESS | STS, ARSA, TST | HSP90AA1 196/4885HSP90AB1 149/4885ALDH1A1 1980/4885 |
| US-20220089598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | HSP90AA1 2227/4885HSP90AB1 1599/4885ALDH1A1 2912/4885 |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | HSP90AA1 1615/4885HSP90AB1 1077/4885ALDH1A1 3409/4885 |
| US-20230242514-A1 | BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR1I2 | HSP90AA1 3178/4885HSP90AB1 2690/4885ALDH1A1 1007/4885 |
| US-20230192666-A1 | PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, NR5A2 | HSP90AA1 1866/4885HSP90AB1 1597/4885ALDH1A1 1874/4885 |
| US-20230045509-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CABOTEGRAVIR | CCR5, SAMHD1, THPO | HSP90AA1 3416/4885HSP90AB1 3134/4885ALDH1A1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.